Harnessing the simplicity of the Enerzair Breezhaler for people with severe asthma

Sponsored by Novartis Pharmaceuticals Australia Pty Ltd

By delivering a once-daily three-drug combination therapy in a single device, the Enerzair Breezhaler (indacaterol, glycopyrronium bromide and mometasone furoate) offers a simplified maintenance combination therapy of long-acting beta2-agonist (LABA), long-acting muscarinic agonist (LAMA), and inhaled corticosteroid (ICS) for people with asthma not adequately controlled on a maintenance LABA-ICS combination.1 The limbic spoke to Professor ...

Already a member?

Login to keep reading.

© 2021 the limbic